Home ›
Acute Lymphoblastic (ALL) Leukemia Trials ›
NCT06880913
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
To evaluate the efficacy and safety of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell therapy in patients with relapsed or refractory B-ALL
Trial Details
NCT ID NCT06880913
Phase PHASE1 / PHASE2
Sponsor Peking University People's Hospital
Status RECRUITING
Cancer Type Acute Lymphoblastic (ALL) Leukemia
Interventions Nanobody-Based CD19/CD22 Tandem Dual CAR-T
Locations (sample) Beijing, Beijing Municipality, China|39.9075,116.39723
Key Eligibility Criteria
The subject or their legally authorized representative (guardian) understands the study and voluntarily signs the informed consent form (ICF). Male or female, aged 12 to 65 years at the time of signing the ICF (inclusive of the cutoff values). Expected survival of at least 12 weeks. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at the time of signing the ICF. At the time of signing the ICF, the patient must be diagnosed with R/R B-ALL and meet the following criteria:
For full eligibility, visit ClinicalTrials.gov .